Atosiban Acetate:Exports & Compliance White Paper 2026

I. Executive Summary

Atosiban acetate (CAS 914453-95-5) is the acetate salt of atosiban, a synthetic cyclic nonapeptide antagonist of the oxytocin receptor with additional vasopressin V1a affinity. Its backbone is Mpa-D-Tyr(Et)-Ile-Thr-Asn-Cys-Pro-Orn-Gly-NH2, with a 3-mercaptopropionyl residue at position 1 joined by a disulfide bridge to Cys6; the free peptide (C43H67N11O12S2, Mr about 994.19) plus acetic acid gives roughly 1054.24. Atosiban is an approved prescription medicine in the European Union and several other markets, so the buying frame is licensed finished-dose manufacture: GMP active substance, a dossier and a validated cold chain.

Supply is therefore a peptide CDMO proposition rather than a catalogue purchase. The material is assembled by Fmoc solid-phase synthesis, incorporating three non-natural elements — the mercaptopropionyl residue, O-ethyl-D-tyrosine and ornithine — before cleavage, oxidative folding, preparative purification, exchange into acetate and lyophilisation. Value per gram is high, and yield is dominated by folding and purification. What separates suppliers is not nominal purity but control of the impurity profile: deletion sequences, epimers, disulfide variants, oxidation products, residual trifluoroacetate, acetic acid, water and peptide content.

This paper sets out the structural and stability characteristics that drive the specification; the solid-phase, folding and salt-formation steps where campaigns succeed or fail; the analytical package regulators expect; the market and capacity picture for GMP peptide suites; the European and United States instruments that apply; the solvent and carbon footprint of solid-phase chemistry; and the cold chain that protects a lyophilised peptide in transit. It is written for sourcing, quality and regulatory professionals at licensed manufacturers and their CDMO partners, and is not medical advice.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Atosiban acts as a competitive antagonist at the oxytocin receptor, blocking the calcium mobilisation and prostaglandin release that drive uterine contraction. The design logic is visible in the sequence: the disulfide ring fixes a turn geometry compatible with receptor binding, the D-configured O-ethyl tyrosine and deaminated mercaptopropionyl residues blunt aminopeptidase attack, and ornithine with a C-terminal amide completes the pharmacophore. The active substance is a hydrophilic lyophilised powder, which is why commercial presentations are parenteral.

• Structural features and receptor selectivity: The 1,6-disulfide bridge, D-Tyr(Et) and C-terminal amidation together determine potency and metabolic stability, so any epimerisation at the D-residue, any alternative disulfide pairing and any des-amido variant are potency-relevant impurities rather than cosmetic ones.
• Stability liabilities of the peptide: Asn5 deamidation, aspartate isomerisation, reduction or scrambling of the disulfide, oxidation of sulfur, aggregation and adsorption to contact surfaces are the documented degradation routes, all pH- and temperature-dependent, which is why the solid is stored frozen, dry and protected from light.

2.2 Synthesis and Manufacturing Technologies

Industrial manufacture is Fmoc/tert-butyl solid-phase synthesis on a resin that generates the C-terminal amide, followed by cleavage, oxidation to close the ring, chromatographic purification, counter-ion exchange and lyophilisation. Development concentrates on four problems: near-quantitative coupling on an aggregation-prone sequence, introducing the non-natural residues without racemisation, folding at a dilution and redox potential that suppress oligomers and scrambled isomers, and converting the trifluoroacetate salt from purification into a defined acetate with reproducible acetic acid content.

• Solid-phase assembly and non-natural residue incorporation: Standard Fmoc amino acids are coupled with modern activating systems, while the mercaptopropionyl unit is introduced as a protected thiol building block, O-ethyl-D-tyrosine as the pre-formed Fmoc derivative and ornithine with side-chain protection; difficult couplings are addressed with elevated temperature, chaotropic salts or pre-formed dipeptides.
• Oxidative folding, purification and acetate salt formation: Cleavage under acidic conditions with scavengers gives the linear dithiol, which is folded in dilute aqueous buffer under air, dimethyl sulfoxide or a glutathione redox couple, then purified by preparative reversed-phase chromatography, exchanged into acetate by ion exchange or repeated lyophilisation from dilute acetic acid, and isolated as a lyophilised powder.

2.3 Core Application Matrix

• Active substance for licensed finished-dose products: The dominant application is supply of GMP peptide active substance to marketing-authorisation holders, under a quality agreement, a change-control regime and a dossier reference such as a certificate of suitability or a drug master file.
• Development, comparability and reference material: Generic and second-source programmes buy development batches, impurity and reference standards, and comparability material for method development and structure confirmation.
• Contract development and technology transfer: Route scouting, folding and purification development, method validation, scale-up into GMP suites and second-source qualification are sold as programmes, where the deliverable is a validated, transferable process rather than a shipment.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand follows the installed base of approved tocolytic therapy and hospital procurement cycles, supplemented by generic entry in Asia and development activity in markets where the product is not authorised. Because alternatives include calcium-channel blockers and other tocolytics, volume is sensitive to national guidelines as well as price. The more important shift for suppliers is that loss of exclusivity and second-source policies have converted a single-source product into a competitive GMP peptide opportunity.

3.2 Capacity Distribution and Export Flows

Capacity is defined by GMP peptide suites rather than by reactors, and is concentrated in Europe, China and India. Solid-phase campaigns are bounded by resin loading and column diameter, so commercial batches typically run at hundreds of grams to a few kilograms, with multi-batch pooling to meet annual demand. Lead times are governed as much by custom Fmoc amino acids, resins and columns as by synthesis time.

3.3 Market Bifurcation and Pricing Dynamics

Pricing is tiered by development stage and documentation. Gram-scale development material is quoted per project with a heavy analytical component; GMP validation batches carry a premium because they absorb process validation, stability set-down and full release testing; commercial campaigns are priced per gram against a forecast. The dominant cost drivers are the custom non-natural amino acids, solvent and resin consumption, purification yield, the release package, cold-chain freight and inspected GMP status.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Because atosiban is an approved medicine, the regulatory burden sits on the active-substance manufacturer in a specific way. ICH Q7 governs GMP for the active substance, ICH Q11 its development and manufacture, and the applicant must reference a certificate of suitability, an active substance master file or a United States drug master file. Peptide-specific expectations — characterisation of related substances, justified thresholds, solvent and reagent control, immunogenicity risk assessment — are what regulators probe at assessment and inspection.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• EU GMP, certificate of suitability or active substance master file: Supply into the European Union requires active-substance GMP compliance documented through inspection or written confirmation, with the substance supported either by a certificate of suitability issued by the European Directorate for the Quality of Medicines or by an active substance master file lodged with the finished-product application, plus openness to inspection of the peptide suite and its cold-chain controls.
• REACH medicinal-products exemption and solvent restrictions: The active substance benefits from the medicinal-products exemption in Article 2(5)(a) of REACH, but the process chemicals do not: N,N-dimethylformamide is restricted under Annex XVII entry 76 and N-methylpyrrolidone under entry 71, which forces solvent substitution or authorised use conditions in solid-phase chemistry, while trifluoroacetic acid faces mounting scrutiny as a persistent per- and polyfluoroalkyl substance.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA expectations for synthetic peptide active substances: Material destined for FDA-regulated drug use is generally outside the TSCA chemical-substance definition, but the facility remains subject to current good manufacturing practice and to inspection. Where the finished product is not authorised in the United States, supply is tied to an active drug master file and to clinical or pre-approval programmes, and sponsors should align with FDA thinking on well-characterised synthetic peptides, including impurity characterisation and qualification.
• Elemental impurities, mutagenic impurities and residual solvents: Elemental impurities are assessed under ICH Q3D, residual solvents under ICH Q3C, and the genotoxic potential of reagents, activating agents and alkylating building blocks under ICH M7, with documented risk assessment rather than end-product testing relied upon for most reagents. Cleaning validation, segregated equipment for peptide synthesis and documented control of the trifluoroacetate load form part of the inspection narrative.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Solid-phase peptide synthesis is among the most solvent-intensive operations in pharmaceutical manufacturing, and its environmental profile is now a qualification topic rather than an internal matter. Buyers with published Scope 3 targets ask how much solvent is consumed per gram of peptide, whether restricted solvents remain in use, how trifluoroacetic acid is recovered or destroyed, and whether site energy use is documented.

5.1 Carbon Footprint and Circular Economy

Process mass intensity in solid-phase synthesis is typically in the thousands, dominated by washing solvents, deprotection base and cleavage acid, with lyophilisation and cold storage adding electrical load. Reduction levers include solvent substitution toward permitted systems, washing optimisation and in-line monitoring, recovery of acetonitrile and trifluoroacetic acid, continuous chromatography, and renewable electricity for freeze-drying.

5.2 Sustainable Sourcing and Traceability

Traceability starts with the amino acids. Fermentation-derived L-amino acids and, critically, the custom O-ethyl-D-tyrosine and protected mercaptopropionyl building blocks must come from qualified suppliers with documented routes, because their impurity profiles propagate into the peptide. Sites should hold an animal-derived-material-free position supported by supplier statements, maintain ISO 9001 and ISO 14001 systems, and provide Scope 1 and 2 data with a Scope 3 narrative covering solvents and cold-chain freight.

VI. Supply Chain Resilience and Export Logistics

Atosiban acetate is a lyophilised, moisture-sensitive peptide normally stored frozen and protected from light, so its logistics are governed by stability rather than hazard class. The active substance is typically not classified as a dangerous good, but its packaging is regulated: dry ice is Class 9, and a temperature excursion destroys value long before a customs issue does. Cold-chain qualification, logger evidence and excursion governance belong in the supplier audit.

6.1 Packaging Standards and Moisture/Contamination Control

• Primary containment: Lyophilised peptide is filled into amber glass vials closed with elastomeric stoppers and oversealed, or into high-density polyethylene bottles, with headspace replaced by nitrogen or argon and each unit packed in a moisture-barrier pouch with desiccant; container closure integrity and extractables data should be available because the substance feeds a parenteral product.
• Qualified cold-chain packaging: Shipments use validated insulated shippers with dry ice or conditioned gel packs, calibrated temperature loggers and outer packaging qualified against recognised thermal profiles, with procedures that prevent condensation on cold vials during opening and that document chain of custody from release to receipt.

6.2 Dangerous Goods Identification and Transit Protocols

The peptide is normally consigned as non-hazardous cargo, while dry ice used as refrigerant is UN 1845, Class 9, shipped under IATA packing instruction 954 with correct marking and declaration; gel-pack systems avoid the dangerous-goods dimension but shorten the qualified transit window. Air freight with controlled handling is preferred, customs documentation should name the substance by CAS number and peptide identity, and every shipment should carry a defined excursion protocol with pre-agreed disposition rules and insurance.

VII. Enterprise Global Expansion Strategy Guide

Peptide CDMOs competing for this work win on three axes: the credibility of the analytical package, the yield economics of folding and purification, and the security of the non-natural building-block supply.

1. Lead with analytical and impurity competence: Build validated methods for identity and sequence confirmation, peptide mapping, liquid chromatography-mass spectrometry, amino acid analysis and chiral verification, qualify reference standards for each specified impurity, and decide early whether the programme will be supported by a certificate of suitability or by a master file, because that decision shapes the specification and the inspection scope.
2. Industrialise folding and purification: Optimise oxidation at workable dilution with defined redox control and in-process monitoring, then raise throughput with stacked injections, multicolumn or continuous chromatography and membrane concentration; every point of purification yield recovered is a direct margin gain on a molecule whose cost is dominated by these steps.
3. Secure inputs and qualify as a second source: Dual-source the custom O-ethyl-D-tyrosine and protected mercaptopropionyl building blocks, hold safety stock of resins and columns, document solvent substitution away from restricted amide solvents, partner with a qualified cold-chain forwarder, and screen buyers for licensed status and declared end use before shipping.

VIII. Conclusion

Atosiban acetate is a demanding but well-defined GMP peptide opportunity. Its difficulty lies not in assembling nine residues but in proving the material is what it claims to be, batch after batch: correct disulfide pairing, correct stereochemistry at the D-residue, a characterised and qualified impurity profile, defined acetate and trifluoroacetate levels, and a cold chain that preserves all of it. Suppliers who internalise that compete on demonstrated control; those who treat the molecule as a commodity lose at first inspection.

For buyers, the guidance is to qualify the analytical package before the price, require impurity reference standards and a justified specification, audit folding, purification and cold-chain qualification rather than only the synthesiser, and hold a second source wherever the product is a single-source authorised medicine. This paper is written for licensed manufacturers and their CDMO partners; it is not medical advice, it contains no dosing or administration guidance, and regulatory positions must be confirmed against current official texts.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Atosiban acetate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Atosiban acetate supply chain:

• China peptide CDMO and building-block base: Chinese producers combine large solid-phase capacity with domestic manufacture of protected amino acids and custom non-natural building blocks, supplying development material, generic-programme active substance and increasingly inspected GMP batches. Their strength is cost and scale in resins, solvents and columns, with rapid turnaround on custom Fmoc derivatives.
• European GMP peptide and dossier hub: European peptide specialists hold the deepest experience with certificate-of-suitability and master-file dossiers, inspected active-substance GMP suites and mature cold-chain and quality-agreement practice, and they anchor supply to marketing-authorisation holders in markets where the product is authorised.
• India and North America development-linked supply: Indian peptide manufacturers pair active-substance capacity with formulation and emerging-market registration experience, while North American CDMOs and analytical specialists serve development, comparability and reference-standard work and support programmes in markets where the finished product is not authorised.